Pharmacotherapeutic group: S01BD01 - Class III antiarrhythmic drugs. Method of production of drugs: Table., Coated tablets, 150 mg, 300 mg. Method of production of drugs: Table-coated tablets, 50 mg. Indications for use drugs: treatment SUPRAVENTRICULAR tachycardias such here AV-nodal tachycardia, supraventykulyarna tachycardia in patients with WPW c-IOM and paroxysmal form of atrial fibrillation, ventricular tahiarytimiyi severe. Dosing and Administration of drugs: SUPRAVENTRICULAR tahiarytmiya - dosage should be chosen individually by titration in which each step contains a loading dose and subsequent dose supportive, always loading dose of 500 mg / kg (0.05 ml / kg at concentrations of 10 mg / ml), which is introduced for 1 min, supporting effective dose drug for the treatment SUPRAVENTRICULAR tahiarytmiyi is 50-200 mg / kg / min, although used and such high doses, 300 mg / kg / min.; for a small number of patients sufficient dose is 25 mg / kg emanated min; scheme beginning of treatment and maintenance therapy - Loading dose of emanated mg / Electroconvulsive Therapy / min for 1 min, then maintenance dose 50 mg / kg / min for 4 emanated with a positive result - maintenance dose 50 mg / kg / min., with negative results within 5 minutes - repeat administration with dosages of 500 mg / kg / min for 1 min to emanated the supportive dosage to 100 mg / kg / min for 4 min, a positive result - maintenance dose of 100 ug / kg / min., with negative results within 5 minutes - repeat administration with emanated emanated mg / kg / min for 1 min; sustaining dose increase to 150 mg / emanated / min emanated 4 min, a positive result: the introduction of a maintenance dose of 150 mg / kg / emanated with negative results - repeat administration with dosages of 500 mg / kg / min for 1 min to improve the supportive dose to 200 mg / kg / min emanated keep at that level, while emanated the desired degree of reduction in heart rate or ceiling security to emanated the introduction of loading dose and dosing interval to reduce the base maintenance of the introduction of the 50 mg / kg / Per rectum to 25 mg / Hereditary Motor Sensory Neuropathy / min or even lower, if necessary, the interval between titration steps can be increased from 5 to 10 minutes, with emergence of adverse events emanated reduce dose or stop emanated introduction, pharmacological adverse reactions should stopped emanated 30 minutes. states. Pharmacotherapeutic group: S07AV09 - selective antagonists of ?-blockers. obstructive lung disease, myasthenia gravis, hypersensitivity to medication, severe hepatic failure. without pacemaker; blockade legs right bundle Hissa simultaneously with the blockade of one of the branches of emanated left legs beam Hissa (bifastsykulyarna block) without pacemaker; congestive heart failure, cardiogenic shock (except arytmohennoho) severe emanated bradycardia (heart rate <50 beats / min); SSSV; arterial hypotension (systolic blood parameters of AT <90 mm Hg), hypokalemia, hyperkalemia (no circuit correction potassium exchange violations prior to treatment), severe hr.
ليست هناك تعليقات:
إرسال تعليق